# Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

> **NCT00005857** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00005857
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** — (—)
- **Last updated:** 2011-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005857, "Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*